We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App

J&J’s Lead COVID-19 Vaccine Candidate Prevents Severe Disease in Pre-Clinical Studies

By HospiMedica International staff writers
Posted on 07 Sep 2020
Print article
Image: J&J’s Lead COVID-19 Vaccine Candidate Prevents Severe Disease in Pre-Clinical Studies (Photo courtesy of Johnson & Johnson)
Image: J&J’s Lead COVID-19 Vaccine Candidate Prevents Severe Disease in Pre-Clinical Studies (Photo courtesy of Johnson & Johnson)
Johnson & Johnson (New Brunswick, NJ, USA) has announced that Janssen Pharmaceuticals Inc.’s (Beerse, Belgium) lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2.

The data demonstrated that the company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease, including weight loss, pneumonia and mortality, in Syrian golden hamsters upon challenge. This publication follows Johnson & Johnson’s recent announcement that its vaccine candidate elicited an immune response in a pre-clinical study in non-human primates (NHP), that correlated with protection against SARS-CoV-2, providing complete protection against viral replication in the lungs. The latest research tested the vaccine candidate in Syrian golden hamsters, as they are more susceptible to clinical disease than NHPs, which typically do not get severe disease.

In the pre-clinical study, researchers first immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all the vaccinated animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2 virus. These vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Mortalities were absent in vaccinated animals. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral replication in the lung. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans.

“This pre-clinical study further validates our confidence in our SARS-CoV-2 vaccine candidate,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “With our Phase 3 trials planned to start this month, we remain committed to expanding our manufacturing and distribution capabilities to enable global access to our SARS-CoV-2 vaccine candidate should it prove to be safe and effective in humans.”

Related Links:
Johnson & Johnson
Janssen Pharmaceuticals Inc.

Print article



view channel

J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions

The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA) to further enable and expand JJMDC’s secure and compliant digital... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.